First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the US Patent and Trademark Office (USPTO) will grant the company’s patent US11,103,481 directed to the use of SCO-101, on August 31, 2021.

The release as fetched from its publisher. scandiononcology.com ↗